| Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats P Fournier, S Boissier, S Filleur, J Guglielmi, F Cabon, M Colombel, ... Cancer research 62 (22), 6538-6544, 2002 | 834 | 2002 |
| Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases S Boissier, M Ferreras, O Peyruchaud, S Magnetto, FH Ebetino, ... Cancer research 60 (11), 2949-2954, 2000 | 832 | 2000 |
| Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer A Boucharaba, CM Serre, S Grès, JS Saulnier-Blache, JC Bordet, ... The Journal of clinical investigation 114 (12), 1714-1725, 2004 | 514 | 2004 |
| Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices S Boissier, S Magnetto, L Frappart, B Cuzin, FH Ebetino, PD Delmas, ... Cancer research 57 (18), 3890-3894, 1997 | 456 | 1997 |
| SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth S Filleur, A Courtin, S Ait-Si-Ali, J Guglielmi, C Merle, A Harel-Bellan, ... Cancer research 63 (14), 3919-3922, 2003 | 375 | 2003 |
| Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity P Clézardin, FH Ebetino, PGJ Fournier Cancer research 65 (12), 4971-4974, 2005 | 300 | 2005 |
| Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone I Pecheur, O Peyruchaud, CM Serre, J Guglielmi, C Voland, F Bourre, ... The FASEB Journal 16 (10), 1266-1268, 2002 | 299 | 2002 |
| Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis F Daubiné, C Le Gall, J Gasser, J Green, P Clézardin Journal of the National Cancer Institute 99 (4), 322-330, 2007 | 282 | 2007 |
| Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases Y Zhao, R Bachelier, I Treilleux, P Pujuguet, O Peyruchaud, R Baron, ... Cancer research 67 (12), 5821-5830, 2007 | 266 | 2007 |
| The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases A Boucharaba, CM Serre, J Guglielmi, JC Bordet, P Clézardin, ... Proceedings of the National Academy of Sciences 103 (25), 9643-9648, 2006 | 259 | 2006 |
| Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer JT Buijs, NV Henriquez, PGM Van Overveld, G Van Der Horst, I Que, ... Cancer research 67 (18), 8742-8751, 2007 | 251 | 2007 |
| Bisphosphonates in cancer therapy V Stresing, F Daubiné, I Benzaid, H Mönkkönen, P Clézardin Cancer letters 257 (1), 16-35, 2007 | 242 | 2007 |
| A cathepsin K inhibitor reduces breast cancer–induced osteolysis and skeletal tumor burden C Le Gall, A Bellahcene, E Bonnelye, JA Gasser, V Castronovo, J Green, ... Cancer research 67 (20), 9894-9902, 2007 | 235 | 2007 |
| Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment … O Peyruchaud, B Winding, I Pécheur, CM Serre, P Delmas, P Clézardin Journal of Bone and Mineral Research 16 (11), 2027-2034, 2001 | 216 | 2001 |
| Effects of bone-targeted agents on cancer progression and mortality R Coleman, M Gnant, G Morgan, P Clezardin Journal of the National Cancer Institute 104 (14), 1059-1067, 2012 | 212 | 2012 |
| Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ... PloS one 6 (4), e19234, 2011 | 207 | 2011 |
| Increased Dickkopf-1 expression in breast cancer bone metastases N Voorzanger-Rousselot, D Goehrig, F Journe, V Doriath, JJ Body, ... British journal of cancer 97 (7), 964-970, 2007 | 207 | 2007 |
| Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast P Clezardin, L Frappart, M Clerget, C Pechoux, PD Delmas Cancer research 53 (6), 1421-1430, 1993 | 207 | 1993 |
| Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class P Clézardin Bone 48 (1), 71-79, 2011 | 200 | 2011 |
| Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature M Gnant, P Clézardin Cancer treatment reviews 38 (5), 407-415, 2012 | 194 | 2012 |
